A 2026 secondary analysis of the ACHIEVE trial found that comprehensive hearing intervention may slow the rise of a blood biomarker linked to neuroinflammation.
In September 2026, researchers published a secondary analysis of the ACHIEVE trial in the journal EClinicalMedicine, reporting that older adults who received a comprehensive hearing intervention showed a significantly slower three-year rise in a blood biomarker associated with neuroinflammation.
The underlying ACHIEVE trial randomized 977 adults aged 70 to 84 with untreated hearing loss to one of two specific groups. Participants received either a comprehensive hearing intervention or a standard health education program. The comprehensive intervention included hearing aids and dedicated audiological support for the duration of the study. The primary trial monitored these participants for three years to measure various long-term health outcomes.
The new secondary analysis included 164 participants who had blood samples available at the beginning of the study. Researchers specifically measured two blood-based markers associated with brain health and dementia progression. The first marker was glial fibrillary acidic protein, commonly known in the medical community as GFAP. GFAP is associated with the activation of astrocytes, which are support cells in the brain that respond to injury and inflammation.
The second marker measured was neurofilament light chain, or NfL. NfL is associated with damage to nerve fibers and broader neurodegenerative processes within the brain. After three years of observation, the researchers noted distinct differences in how these two specific markers changed in the different groups. GFAP rose in the health education group but remained essentially stable in the hearing intervention group.
This stable GFAP trajectory produced a statistically significant difference between the two trial groups. NfL also rose more slowly in the hearing intervention group, but that specific difference did not reach statistical significance. Lead author James Russell Pike and his colleagues wrote that the results suggest hearing intervention may reduce the progression of non-specific biomarkers of neuroinflammation. This potential reduction applies particularly to older adults with hearing loss who have multiple risk factors for incident dementia.
These findings offer practical direction for adults who are proactively managing their long-term health. Older adults should treat hearing assessment as a normal part of broader preventive healthcare rather than just a late response to severe communication difficulty. The ACHIEVE biomarker results provide a clear biological reason to discuss untreated hearing loss with a qualified clinician. Taking action early can support daily communication while you continue reading about brain aging and neuroplasticity.
A practical first step is arranging a hearing evaluation if you notice specific daily challenges. You might consider an assessment if conversations are frequently missed, or if speech is difficult to follow in noisy environments. Other common signs include needing a higher television volume or family members repeatedly reporting that you are not hearing well. A 2026 review found that hearing aids are likely to improve listening ability and hearing-specific quality of life in adults with mild to moderate hearing loss.
If a clinician recommends hearing aids, the type of professional care you receive matters significantly. The ACHIEVE study tested a comprehensive intervention that involved ongoing audiological care and continuous support. The intervention was not merely the quick purchase of an over-the-counter device without assessment or professional follow-up. A comprehensive approach prioritizes professional fitting, careful adjustment, and regular follow-up visits.
Focusing on a complete care plan is a valuable part of cognitive health protection. You should also maintain other established routines like managing cardiovascular risk, staying physically active, and addressing sleep concerns. The current analysis tested a specific hearing intervention rather than a complete dementia prevention lifestyle program. Combining hearing care with other evidence-based habits safely supports your overall well-being.
While the blood biomarker findings are biologically relevant, readers must interpret the primary trial results carefully. Across the full 977-person sample, the parent ACHIEVE trial found no statistically significant difference in overall cognitive decline between the two groups over three years. Hearing intervention did not significantly slow the three-year change in global cognition for the entire study population. Therefore, the trial does not support the broad claim that hearing aids automatically prevent cognitive decline for every older adult with hearing loss.
The researchers themselves described the blood biomarkers as non-specific indicators. GFAP and NfL are associated with brain health and dementia progression, but they are not definitive diagnostic tests for dementia or Alzheimer’s disease. A positive change in either marker does not automatically demonstrate that a person’s memory or daily independence has improved. The investigators noted that the findings strengthen the case for hearing loss as a modifiable target, but they explicitly stated that this is an association with biomarker trajectories.
The new analysis does not prove that hearing treatment prevents dementia in the general population. It is also important to note that this was a secondary analysis of a smaller subset. Because the biomarker sample was a subset of only 164 people, its results may not generalize to all older adults with hearing loss. The statistically significant result applied only to the neuroinflammation-associated marker, GFAP.
The trial did find stronger cognitive signals in specific higher-risk groups, which requires careful context. A prespecified subgroup analysis showed that participants from the higher-risk ARIC cohort experienced approximately 48 percent slower cognitive decline with hearing intervention. Another later risk-stratified analysis reported that participants in the highest quarter of predicted cognitive-decline risk had 61.6 percent slower three-year cognitive decline. These subgroup effects are secondary evidence requiring confirmation and do not represent a universal treatment effect.
A separate pooled analysis reported that hearing aid users had a 9 percent lower probable-dementia hazard than non-users. However, that evidence was observational rather than randomized, meaning it cannot establish that hearing aid use actually caused the lower risk. All of these nuances mean that hearing care is a supportive tool rather than a guaranteed medical cure. Maintaining a broad perspective on lifestyle and brain resilience remains the most practical approach for older adults.
The sector evidence is clearly moving toward a more nuanced model of hearing and cognitive health. Treating hearing loss has established, measurable benefits for daily communication and social participation. The new secondary analysis shows that comprehensive hearing care may also influence biological pathways linked with brain aging, especially those related to inflammation. These developments reinforce hearing care as a meaningful, modifiable health factor for older adults.
However, the potential effects on cognition and dementia-related biology appear heavily dependent on baseline risk and the specific study population. Hearing care is not a standalone prevention strategy for cognitive decline or memory loss. It is one practical component of a comprehensive approach to aging well. Staying informed about the science helps you make confident, realistic decisions for your long-term health.
Primary care doctors and older adults manage the daily challenge of navigating new hearing intervention data, and health planning becomes much easier when FitBrainLab clarifies these biomarker studies. Conflicting advice about nutrition, exercise, sleep, supplements and brain performance often creates confusion, but our clear editorial guidance helps you build practical habits without fear-based marketing.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
